Dr. Scott Schuetze, MD, PhD
Claim this profileUniversity of Michigan Comprehensive Cancer Center
Studies Liposarcoma
Studies Cancer
11 reported clinical trials
17 drugs studied
Area of expertise
1Liposarcoma
Stage IV
Stage III
MDM2 positive
2Cancer
Stage IV
Stage III
FGFR positive
Affiliated Hospitals
Clinical Trials Scott Schuetze, MD, PhD is currently running
Adoptive Cell Therapy
for Cancer
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Recruiting1 award Phase 1
Low-Dose Chemotherapy + Anti-Cancer Drug
for Sarcoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.
Recruiting1 award Phase 1
More about Scott Schuetze, MD, PhD
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Scott Schuetze, MD, PhD has experience with
- Nivolumab
- Doxorubicin
- BI 907828
- Paclitaxel
- Rogaratinib
- Pegylated Liposomal Doxorubicin Hydrochloride
Breakdown of trials Scott Schuetze, MD, PhD has run
Liposarcoma
Cancer
Soft Tissue Sarcoma
Synovial Sarcoma
Esophageal Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott Schuetze, MD, PhD specialize in?
Scott Schuetze, MD, PhD focuses on Liposarcoma and Cancer. In particular, much of their work with Liposarcoma has involved Stage IV patients, or patients who are Stage III.
Is Scott Schuetze, MD, PhD currently recruiting for clinical trials?
Yes, Scott Schuetze, MD, PhD is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Scott Schuetze, MD, PhD has studied deeply?
Yes, Scott Schuetze, MD, PhD has studied treatments such as Nivolumab, Doxorubicin, BI 907828.
What is the best way to schedule an appointment with Scott Schuetze, MD, PhD?
Apply for one of the trials that Scott Schuetze, MD, PhD is conducting.
What is the office address of Scott Schuetze, MD, PhD?
The office of Scott Schuetze, MD, PhD is located at: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.